Dr. Tafadzwa Muguwe is a strategy business partner at Foundation Medicine, a world-leading molecular information company focusing on cancer genomic tests. Previously, he was an associate in the healthcare practice at McKinsey & Company in Palo Alto, CA. Preceding that, he completed residency in internal medicine at Mount Auburn Hospital in Cambridge, MA and also served as a resident tutor for undergraduates in Cabot House at Harvard College. He received his M.D. degree from the Health Sciences and Technology (HST) program at Harvard and MIT. He completed Ordinary and Advanced Level at Kutama High School and entered Swarthmore College on a full scholarship, graduating Phi Beta Kappa with a B.A. in biology. At graduation he received the Ivy Award, 'given by vote of the faculty to the senior man outstanding in leadership, scholarship, and contribution to the college community'. He subsequently spent two years as a Rhodes Scholar in Oxford where he read for M.Sc. degrees in immunology and global health. Tafadzwa is also a marathon-enthusiast and has completed 4 races to date. He closely follows professional tennis and soccer.
Dr. Stephen F. Kingsmore is President/CEO of Rady Children's Institute for Genomic Medicine where he leads a multi-disciplinary team of scientists, physicians and researchers who are pioneering the use of rapid Whole Genome Sequencing to enable precise diagnoses for critically-ill newborns.
Among his achievements, Dr. Kingsmore holds the Guinness World Record for achieving the fastest molecular diagnosis using whole genome sequencing in just 19.5 hours.
Before being selected to lead RCIGM, he was the Dee Lyons/Missouri Endowed Chair in Genomic Medicine at the University of Missouri-Kansas City School of Medicine and Director of the Center for Pediatric Genomic Medicine at Children's Mercy Hospital, Kansas City. Dr. Kingsmore received MB ChB BAO BSc and DSc degrees from the Queen's University of Belfast. He trained in clinical immunology in Northern Ireland and did residency in internal medicine and fellowship in rheumatology at Duke University Medical Center.
Simba is an experienced and motivated impact investment executive who aims to use his financial expertise, business acumen, leadership skills and global networks to finance businesses that empower underserved and financially excluded communities and individuals. He is the Head of Investment Solutions at Brightlight Group in Sydney, Australia. Prior to that, he spent 6 years managing Christian Super’s alternatives, fixed income and Impact Investment portfolios where he helped to commit close $150 million to Impact Investments. He is also Co-Founder of Ignition Impact, and EdFin companies.
Nyasha is a trained molecular vaccinologist currently registered with the Medical Laboratory and Clinical Scientist Council of Zimbabwe as a medical microbiologist. He holds a Bachelor of Science Honours in Biological Sciences and a Master of Science in Biotechnology from the University of Zimbabwe as well as a PhD in Medical Microbiology from the University of Cape Town. His doctoral research interrogated the development and testing of attenuated recombinant bacterial-based HIV/AIDS vaccines. After doctoral studies, he was awarded a postdoctoral fellowship under the South African Vaccinology Research Chair programme to do further research on DNA-based HIV/AIDS vaccines in the Division of Medical Virology of the University of Cape Town. He was later awarded a second postdoctoral vaccinology research fellowship at Emory Vaccine Centre in the United States. After a stint at Emory University, he returned to South Africa to take up another postdoctoral fellowship in pharmacogenomics in the Division of Human Genetics of the University of Cape Town. Nyasha is currently a full professor at the University of Zimbabwe and teaches biotechnology, microbiology, virology, vaccinology, molecular biology and genomics to medical and science students.